Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Ubiquinol, the reduced and active antioxidant form of Coenzyme Q10 (CoQ10), has been investigated for its potential benefits in neurodegenerative diseases, including Multiple Sclerosis (MS). The rationale for its use is based primarily on its role in mitochondrial energy production and its antioxidant properties, which may counteract the increased oxidative stress and mitochondrial dysfunction observed in MS patients. Several small-scale clinical trials and animal studies have explored the effects of CoQ10 (often as ubiquinone, but sometimes as ubiquinol) supplementation in MS, with mixed results. Some studies suggest minor improvements in fatigue and oxidative stress markers, but robust, consistent clinical benefits on MS progression, disability, or relapse rates have not been demonstrated.

A 2015 randomized controlled trial found that CoQ10 supplementation (500 mg/day) in relapsing-remitting MS patients led to modest improvements in fatigue and depression scores over 12 weeks, but these findings have not been widely replicated or confirmed for ubiquinol specifically. The evidence base remains small and is limited by short study durations, small sample sizes, and lack of long-term outcome data. Major clinical guidelines for MS do not recommend ubiquinol or CoQ10 as a standard therapy. Thus, while the theoretical basis and some preliminary evidence exist, the scientific validation is weak and further research is necessary to establish clinical efficacy.

More about ubiquinol
More about Multiple Sclerosis

Other ingredients used for Multiple Sclerosis

Other health conditions supported by ubiquinol

Products containing ubiquinol